NCT06093152View on ClinicalTrials.gov

Video Assisted Study of Salbutamol Response in Viral Wheezing

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

October 23, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Wheezing
Interventions
DRUG

Salbutamol

Inhaled salbutamol (SABA, selective beta2-adrenergic receptor agonist) 0,1 mg 4-6 puffs 3-4 times every 20 minutes administered by OptiChamber holding chamber.

Trial Locations (1)

90130

RECRUITING

Department of Pediatrics, Oulu University Hospital, Oulu

All Listed Sponsors
lead

University of Oulu

OTHER